BIBLIOGRAPHY

BIBLIOGRAPHY

Ackermann, M.F., K.R. Lamm, W.G. Wiegand and M.I. Luster. 1989. Antitumor activity of murine neutrophils demonstrated by cytometric analysis. *Cancer Res.* 49 : 528

Adams, D. O. and T.A. Hamilton. 1984. The cell biology of macrophage activation. *Annal. Rev. Immunol.* 2 : 284

Alexander, P. 1974. Escape from immune destruction by the host through shedding surface antigens : Is this a characterestic shared by malignant and embryonic cells? *Cancer Res.* 34 : 2077

Alexander, P. 1975. Mechanism of escape of antigenic tumors from host control IN : *Biology of Cancer.* Ambrose, E. J. and F. J. C. Roe. eds. Ellis Harwood Ltd. Chichester.

Allavena, P., F. Zanaboni, S. Rossini. 1986. Lymphokine activated killer activity of tumor associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors. *J. Natl. Cancer. Inst.* 77 : 863

Alleva D.G., C.J. Burger and K.D. Elgert. 1994. Tumor-induced regulation of suppresser macrophage nitric oxide and TNF-α production : role of tumor-derived IL-10, TGF-B, and prostaglandin E_2. *J. Immunol.* 153 : 1674

Alverez, J.M., M.O. de Landazuri, G.D. Bonnard and R.B. Herberman. 1978. Cytotoxic activity of normal cultured human T cells. *J. Immunol* 121 : 1270

Andreesen, R. 1993. Macrophage-directed tumor immunotherapy revisited-past and future of an old doctors' dilemma. *Res. Immunol.* 144 : 291

Anaclerio, A.A., J.D. Waterfield, G. Moller. 1974. Induction of lymphocyte mediated cytotoxicity against allogeneic tumor cells by Concanavalin A *in vivo*. *J. Immunol* 113 : 870

Anderson, J., G.M. Edelmanx, G. Moller and O. Sjoberg. 1972. Activation of B lymphocytes by locally concentrated Concanavalin A. *Eur. J. Immunol* 2 : 233.

Axel, R. 1975. Cleavage of DNA in nuclei and chromatin with staphylococcal nuclease. *Biochemistry* 14 : 2921.

Bach, F.H., M. Segall, K.S. Zier, P.M. Sondel, B.J. Alter and M.L. Bach. 1973. Cell mediated immunity : separation of cells involved in recognitive and destructive phases. *Science* (Wash. D.C.) 180 : 40

Baker, P.E, S. Gillis and K.A. Smith. 1979. Monoclonal cytotolytic T cell lines. *J. Exp. Med.* 149 : 273

Baldwin, R.W., M.R. Price, R.A. Robbins. 1972. Blocking of lymphocytes mediated cytotoxicity for rat hepatoma cells by tumor specific antigen-antibody complexes. *Nature*. 238 : 185

Baldwin, J.P., P.G. Boseley, M. Bradbury, K. Ibel. 1975. The subunit structure of the eukaryotic chromosome. *Nature* (London) 253 : 245

Barba, D., H.E. Oldfield, S.C. Saris, S.A. Rosenberg, J.M. Hamilton. 1988. Phase II immunotherapy of cystic primary brain tumors (PBT) with IL-2/LAK cells. *Proc. Am. Soc. Clin. Oncol.* 7 : 82

Bear, H.D., B.M. Susskind, K.A. Close and S.K. Barret. 1988. Phenotype of syngeneic tumor-specific cytotoxic T lymphocytes and requirements for their *in vitro* generation from tumor-bearing host and immune spleens. *Cancer Res.* 48 : 1422.

Belldegrun, A., D.E. Webb, H.J. Austin, S.M. Steinberg, D.E. White, W.M. Lineham and S.A. Rosenberg. 1987. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. *Ann. Int. Med.* 106 : 817

Belldegrun, A., L.M. Muul, S.A. Rosenberg. 1988. Interleukin 2 expanded Tumor Infiltrating Lymphocytes in human

renal cell cancer : Isolation, characterization and antitumor activity. *Cancer Res.* 48 : 206

Belldegrun, A., A. Kasid, M. Uppenkamp, S.L. Topalian and S.A. Rosenberg. 1989. Human analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. *J. Immunol.* 142 : 4520

Ben Sasson, S.Z., W.E. Paul, E.M. Shevach, and I. Green. 1975. *In vitro* selection and extended culture of antigen-specific T lymphocytes. *J. Exp. Med.* 142 : 90

Berendt, M.J. and R.J. North. 1980. T-Cell mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. *J. Exp. Med.* 151 : 69

Berkowitz. E.M. and P. Doty. 1975. Chemical and physical properties of fractionated chromatin. *Proc. Natl. Acad.* USA. 72 : 3328

Betz, E.H. and L.J. Simar. 1974. Immune cellular mechanism at the site of tumor. IN: *Clinical Tumor Immunology*. Wybran, J. and M. Stagnet. eds. Pergamon Press. pp. 19.

Bevan, M.J. and M. Cohn. 1975. Cytotoxic effects of antigen and mitogen-induced T cells on various targets. *J. Immunol.* 114 : 559

Bilik, R., C. Mor, B. Hazaz and C. Morz. 1989. Characterization of T-lymphocyte subpopulations infiltrating primary brest cancer. *Cancer Immunol. Immunother.* 28 : 143

Billing R.J. and J. Bonner 1972. The structure of chromatin as revealed by deoxyribonuclease digestion studies. *Biochem. Biophys. Acta.* 281 : 453

Bonavida, B. 1977. Con A mediated activation of antigen primed lymphocytes into secondary cytotoxic lymphocytes. *J. Exp. Med.* 145 : 293

Bonnard, G.D., D.J. Schended, W.J. West, J.M. Alvarez, R.D. Maca, K. Yasaka, R.L. Fine, R.B. Herberman, M.O.

de Landayuri and D.A. Morgan. 1978. Continued growth of normal human T lymphocytes in culture with retention of important functions. In : *Human Lymphocyte Differention : Its application to Cancer.* Edited by B. Serrov and C. Rosenfeld. Elsevier,North-Holland Biomedical Press, Amsterdam. pp. 319

Borberg, H., H.F. Oettgen, K. Choudry and E.J. Beattie, Jr. 1972. Inhibition of established transplants of chemically induced sarcomas in syngenieic mice by lymphocytes from immunized donars. *Int. J. Cancer.* 10 : 539

Brawn, R.J. 1970. Possible association of embryonal antigen(s) with several primary 3-Methylcholanthrene-induced murine sarcomas. *Int. J. Cancer.* 6 : 245

Burgoyne, L.A., D.R. Hewish and J. Mobbs. 1974. Mamalian chromatin substructure studies with the calcium magnesium endonuclease and two dimensional polyacrylamide electrophoresis. *Biochem. J.* 143 : 67

Buchmuller, Y., W.Y. Weiser and H.G. Remold. 1985. Partial purification and characterization of human lymphokine which induces antileishmanial activity in mouse macrophage. *Cellular Immunol.* 90. 242

Byrne, J.A., J.L. Butler and M.D. Cooper. 1988. Differential activation requirements for virgin and memory T cells. *J. Immunol.* 141 : 3249

Byrne, J.A., J.L. Butler, E.L. Reinherz and M.D. Cooper. 1989. Virgin and memory T cells have different requirements for activation via the CD2 molecule. *International Immunology.* 1 : 29

Cameron, D.J. 1983. Inhibitory factors derived from human tumors : isolation of factors which suppress macrophage mediated cytotoxicity. *Int. J. Immunopharmac.* 5 : 345

Cantor, H. and J. Jandenski. 1974. The relationship of cell division to the generation of cytotoxic activity in mixed lymphocyte culture. *J. Exp. Med.* 140 : 1712

Cantor, H. and E. Simpson. 1975. Regulation of the immune response by subclasses of T lymphocytes. I. Interaction between pre-killer T cells and regulatory T cells obtained from peripheral lymphoid tissues of mice. *Eur. J. Immunol.* 5 : 330

Catalona, W.J., T.L. Rateliff, and R.E. McCool. 1980. Concanavalin A activated suppressor cell activity in peripheral blood lymphocyte of urologic cancer patients. *J. Natl. Cancer Inst.* 63 : 553

Cerottini, J.C. and K.T. Bruner. 1974. Cell mediated cytotoxicity allograft rejection and tumor immunity. *Adv. Immunol.* 18 : 67

Chakravarty, A.K. 1977. An *in vitro* study of functional maturation of murine thymus cells. *Differentiation.* 8 : 21

Chakravarty, A.K. and W.R. Clark. 1977. Lectin-driven maturation of cytotoxic effector cells : The *nature* of effector memory. *J. Exp. Med.* 146 : 230

Chakravarty, A.K. and T.K. Choudhry. 1983. Corelation of blastogenesis and DNA synthesis in the murine lymphocytes during *in vivo* activation with Concanavalin A. *Jap. J. of Med. Sci and Biol.* 36 : 43

Chakravarty A.K. and U.K. Maitra. 1983. Inhibition of tumori induced angiogenesis and tumor growth by activated lymphocytes. *Experientia.* 39 : 542

Chakravarty, A.K. and U.K. Maitra. 1990. Polyclonally stimulated murine T cells in control of fibrosarcoma in situ. *J. Ind. Ins. Sci.* 70 : 503

Chakravarty, A.K. and S. Jha. 1996. Post operative immunotherapy of malignancy in mouse with adoptive transfer of suppressor cell depleted polyclonally activated syngeneic T cells. (Communicated).

Charmot, D., C.E. Mawas and M. Sasportes. 1975. Secondary response in *in vivo* primed human lymphocytes to allogenic reaction stimulating determinants and non-

specific mitogens, in the generation of secondary cytotoxic effectors. *Immunogenetics.* 2 : 465

Cheever, M.A., R.A. Kempf and A. Fefer. 1977. Tumor neutralization immunotherapy and chemotherapy of Friend leukemia with cells secondarily sensitized *in vitro*. *J. Immunol.* 119 : 714

Cheever, M.A., R.A. Kempf, P.D. Greenberg, A. Fefer and S. Gillis. 1982. Augmentation of antitumor therapeutic efficacy of longterm cultured T lymphocytes by *in vivo* administration of purified interleukin-2. *J. Exp. Med.* 155 : 968

Chaudhuri, T.K. and A.K. Chakravarty. 1981. Activation of murine thymocytes *in vivo*. Part I. Study of blastogenesis and DNA synthesis after stimulation with Concanavalin A. *J. Ind. Inst. Sci.* 63 : 149

Chaudhuri, T.K. and A.K. Chakravarty. 1983. Study of murine lymphoid cells *in situ*. after stimulation with Concanavalin A. *Japan J. Med. Sci. and Biol.* 36 : 97

Chaudhuri, T.K. 1983. Mitogen mediated activation of murine T cells *in vivo* for immunological functions. Ph.D. Thesis. University of North Bengal.

Christensen, N.D., J.W. Kreider and R.L. Horetsky. 1988. Suppressor lymphokine produced by rat T cells in response to syngeneic mammary adenocarcinoma 13762A. *Cancer Res.* 48 : 943

Cochran A. J. 1969. Histology and prognosis in malignant melanoma. *J. Pathol.* 97 : 459

Coggin, J.H. Jr. and N.J. Anderson. 1974. Cancer dedifferentiation and embryogenic antigens : Some central problem. Adv. *Cancer Res.* 19 : 105

Coutintio, A., E. Gronowicz and G. Moller. 1975. Signals and receptors in B cell activation. IN: *Immune Recognition*. A.S. Rosenthal, ed. New York Acad. Press, pp. 63

Crowley, N.J., T.L. Darrow, M.A. Quinn-allen and H.F. Seigler. 1991. MHC-restricted recognition of autologus melanoma by tumor-specific cytotoxic T-cells. Evidence for restriction by a dominant HLA-A allele. *J. Immunol.* 146 : 1692

Currie, G.A. and C. Basham. 1975. Activated macrophages releases a factor which lyses malignant cells but not normal cells. *J. Exp. Med.* 142 : 1600

Cuturi, M.C., M. Murphy, M.P. Costa-Giomi, R. Weinmann, B. Perussia and G. Trinchieri. 1987. Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocyte. *J. Exp. Med.* 165 : 1581

Daynes, R.A., M.K. Schmitt, L.K. Robertes and C.W. Spellman. 1979. Phenotypic and physical characteristic of lymphoid cells involved in the immunity to syngeneic UV-induced tumours. *J. Immunol.* 122 : 2458

Dennert, G. and M. DeRose. 1976. Continuously proliferating T killer cells specific for H-2^b targets : Selection and characterization. *J. Immunol.* 116 : 1601

den Otter, W.R. Evans and P. Alexander. 1972. Cytotoxicity of murine peritoneal macrophages in tumor allograft immunity. *Transplantation.* 14 : 220

Disis, M.L., E. Calenoff, G. McLaughlin, A.E. Murphy, W. Chen, B. Groner, M. Jeschke, N. Lydon, E. McGlymn, R.B. Livingston, R. Moe and M.A. Cheever. 1994. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. *Cancer Res.* 54 : 16

Donohue, J.H., M. Rosenstein, A.E. Chang, M. T. Lotze, R.J. Robb and S.A. Rosenberg. 1984. The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. *J. Immunol.* 132 : 2123

Eberlein, T., J.M. Rosenstein and S. A. Rosenberg. 1982. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in IL-2. *J. Exp. Med.* 156 : 385

Ehrlich, R. M. Efrate and I.D. Witz. 1980. In: *Natural cell-mediated immunity against tumors*. Herberman R.B. ed. Academic Press. N.Y. pp. 1073

El-Deiry S.W. , T.Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W. E. Mercer, K.W. Kinzler and B. Vogelstein. 1993. WAF1, Apotential mediator of p53 tumor suppression. *Cell.* 75 : 817

Evans, R. and P. Alexander. 1970. Cooperation of immune lymphoid cells with macrophages in tumor immunity. *Nature.* 228 : 620

Evans, R. 1976. Tumor macrophages in host immunity to malignencies. IN. *Macrophages in neoplasi.* Fink, MA., ed. Academic Press, N.Y. pp. 27

Evans, D.L., D.V. Parkar and M.K. Frank. 1979. Biochemical and physical characterization of tumor associated fetal antigens. *Cancer Res.* 39 : 2006

Evans, R. and E.M. Lawler. 1980. Macrophage content and immunogenecity of C57BL/6J and BALB/CByJ methylcholanthrene induced sarcomas. *Int. J. Cancer.* 26 : 831

Fernandez- Cruz, E.,B. Halliburton and J.D. Feldman. 1979. *In vivo* elimination by specific effector cells of an established syngeneic rat Moloney virus- induced sarcoma . *J. Immunol* 123 : 1772

Fernandez-Cruz, E., B.A. Woda and J.D. Feldman. 1980. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. *J. Exp. Med.* 152 : 823

Ferradini, L., A. Mackensen, C. Genevee, J. Bosq, P. Duviflard, M. Avril, and T. Hercend. 1993. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes

from a human regressive melanoma. *J. Clin. Invest.* 91 : 1183

Flint S.J. and H.M. Weintraub. 1977. An altered configuration associated with actively transcribed DNA of integrated Adenovirus genes. *Cell.* 12 : 783

Foe, V.E. , L.E. Wilkinson and C.D. Laird. 1976. Comparative organization of active transcription units in Oncopeltus fusciatus. *Cell.* 9 : 131

Folly, E.J. 1953 . Antigenic properties of Methylcholanthrene induced tumors in mice of strain of origin. *Cancer Res.* 13 : 835

Fredman L. R., J.C. Cerottine and K. T. Brunner. 1972. *In vivo* studies in the role of cytotoxic T cells in tumor allograph immunity. *J. Immunol.* 109 : 1371

Fredman, S.O. 1974. Carcinoembryonic Antigens : Clinical aspects. Conf. Symp. Workshop. XI. Int. Cancer Congress. Florence. pp. 172

Garel A. and R. Axel. 1976. Selective digestion of transcriptionally active ovalbumin genes from oviduct nuclei. *Proc. Natl. Acad. Sci.* USA. 73 : 3966

Garel, A., M. Zolan and R. Axel. 1977. Genes transcribed at diverse rates have similar conformation in chromatin. *Proc. Nat . Acad. Sci.* USA. 74 : 4867

Georopoulos, K., P. van den Elsen, E. Bier, A. Maxam and C, Terhorst. 1988. A T cell specific enhancer is located in a DNase I hypersensitive area at 3' end of the CD-d gene. *E.M.B.O.J.* 7 : 2401

Gerson J.M. 1980. In: Natural cell-mediated immunity against tumors. Herberman R.B. ed. Academic Press. N.Y.

Gershon, R.K., P. Cohn, R. Heneir and S.A. Leibhaber. 1972. Suppressor T cells. *Immunol* 108 : 586

Groudine M., S. Das, P. Neiman and H. Weintraub. 1978. Regulation of expression and chromosomal subunit

conformation of avian retrovrius genomes. *Cell.* 14 : 865

Gillis, S. and K.A. Smith. 1977. Long term culture of tumor specific cytotoxic T cells. *Nature* 268 : 154

Gillis, S., P.E. Baker, F.W. Ruscetti and K.A. Smith. 1978. Long term culture of human antigen-specific cytotoxic T cell lines. *J. Exp. Med.* 148 : 1093

Goedegebuure, P.S., K.Y. Le Y.M. Matory, G.E. Peoples, I. Yoshino and T.J. Eberlin. 1994. Classification of $CD4^+$ T helper cell clones in human melonoma. *Cell. Immunol.* 156 : 170

Goedegebuure P.S. and T.J. Eberlin. 1995. The role of $CD4^+$ tumor infiltrating lymphocytes in human solid tumors. *Immunol.* Res. 14 : 119

Goedegebuure P.S., W. Harel, L.G. LeMay, J. K. Mitchell and M.S. Mitchell. 1993. Cytotoxic $CD4^+$ lymphocyte clones reactive with melanoma : The role of HLA and accessory molecules. *Vaccine Res.* 2 : 249

Gollahan K.A. 1976. Use of mixed hemadsorption assay to evaluate humoral antibody level in mice with Methylcholantherene induced tumors. Master thesis, University of Missouri at Kansas City.

Golub, S.H., D. Rangel and D.L. Morton. 1977. *In vitro* assessment of immunocompetence in patients with malignant melanoma. *Int. J. Cancer.* 20 : 873

Gorelik E., R. Without, K. Okumura, S. Habu and R.B. Herbermanm. 1982. In "NK cells and other natural effector cells." Herberman R.B. ed. Academic Press, N.Y. pp. 1331

Gottesfeld J. M., J. Bonner, G.K. Radda and I.O. Walker. 1974. Biophysical studies on mechanism of quinacrine staning of chromosome. *Biochemistry.* 13 : 2937

Gottesfeld, J.M., R.F. Murphy and J. Bonner. 1975. Structure of transcriptionally active chromatin. *Biochemistry*. 72 : 4404

Green, M.I. 1981. Tumour immunity and MHC. IN. *The role of MHC in immunology*. Dorff, M.S. ed. Garland STPM Press. N.Y. pp. 373

Green, W.R., Z.K. Ballas and C.S.Hennery. 1978. Studies on the mechanism of lymphocyte-mediated cytolysis. XI. The role of lectin in lectin dependent cell mediated cytotoxicity. *J. Immunol.* 121 : 1566

Greene, W.L. and W.J. Leonard. 1986. The human interleukin-2 receptor. *Annu. Rev. Immunol.* 4 : 69

Griffith. J. 1970. Ph.D. Dissertation, California Institute of Technology, Pasadema, California.

Griffith J.D. 1975. Chromatin Structure : Deduced from a minichromosome. *Science*. 187 : 1202

Griffith.J. D. 1978. DNA structure: Evidence from electron microscopy. 1978. *Science* 187 : 1202.

Grimm, E.A., A. Mazumder and S.A. Rosenberg. 1982a. *In vitro* growth of cytotoxic human lymphocytes. V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by cellular immune supplementation of *in vitro* sensitization with partially purified TCGF. *Cell. Immunol.* 70 : 248

Grimm, E.A., A. Mazumder, H.Z. Zhang and S.A. Rosenberg. 1982b. Lymphokine activated killer cell phenomenon. Lysis of natural of natural killer resistant fresh solid tumor cells by interleukin 2 activated autologus human peripheral blood lymphocytes. *J. Exp. Med.* 155 : 1823

Grimm, E.A. and S.A. Rosenberg. 1982c. Production and properties of human IL-2. IN. *Characterization and utilization of T lymphocyte clones*. G. Fathman and F. Fitch, ed. Academic Press, Inc. N.Y. pp. 57

Gross, D.S. and W. Garrad. 1988. Nuclease hypersensitivity sites in chromatin. *Annu. Rev. Biochem.* 57 : 159

Grosveld, F., G. B. van Assendelft, D.R. Greaves, D.R., and G. Kollias. 1987. Position-independent high-level expression of human β-globin gene in transgenic mice. *Cell.* 51 : 975

Gurvey, M.E., B.R. Apatoft, G.T. Spear, M.J. Baumel, J.P. Antel, M.B. Bania and A.J. Reder. 1986. Neuroleukin : a lymphokine product of lectin stimulated T cells. *Science.* 234 : 574

Hagman, J., C.M. Rudin, D. Haasch, D. Chaplin, and U. Storb. 1990. A novel enhancer in immunoglobulin L locus is duplicated and functionally independent of NF_kB. *Genes Dev.* 4 : 978

Haprer, G.H., L. Stolbach, M. Byrne, F.J. Cummings, E. McDoonugh and P. Calabrest. 1973. Cell mediated and serum blocking reactivity of tumor antigens in patients with malignant melonoma. *Int. J. Cancer.* 11 : 245

Hansen, M.G. and A.B. McCarten. 1974. Tumor thickness and lymphocytic infiltrations in malignant melanoma. *Am. J. Surg.* 128 : 557

Harel, W., P.S. Goedegebuure., L.G. LeMay, H.O. Huang, J. K. Mitchell and M.S. Mitchell, R. Hirai, Y. Oguchi, N. Sugita, K. Matsunaga and K. Nomoto. 1993. Enhancement of T-cell proliferation by PSK. *Int. J. Immunopharmacol.* 15 : 745

Hayry, P. and T. H. Totterman. 1978. Cytological and functional analysis of inflamatory infiltrates in human malignant tumors. I. Comparison of inflamatory infiltrates. Europ. *J. Immunol.* 8 : 866

Haskonee, C. and P. Angelisova. 1975. *In vivo* responsiveness of lymphocytes of different mouse strains to phytohemagglutinin. Falia. Biologica (Praha). 21 : 15

Heinenger, D, M. Touton, A.K. Chakravarty and W.R. Clark. 1976. activation of cytotoxic function in T lymphocytes. *J. Immunol.* 117 : 2175

Hellstrom, I. and K.E. Hellstrom. 1969. Studies on cellular immunity and its serum mediated inhibition in moloney virus-induced mouse sarcomas. *Int. J. Cancer.* 4 : 587

Hellstrom, I., and K.E. Hellstrom. 1970. Colony inhibition studies on blocking and non blocking serum effects on cellular immunity of Moloney sarcomas. *Int. J. Cancer.* 5 : 195

Hellstrom, I. , K.E. Hellstrom. and H.O. Sjogren. 1971. Demonstration of cell mediated immunity to human neoplasm of various histological types. *Int. J. Cancer.* 7 : 1

Hellstrom, I., G.A. Warner, K.E. Hellstrom.and H.O. Sjogren. 1973. Sequential studies on cell mediated tumor immunity and blocking serum activity in ten patients with malignant melonoma. *Int. J. Cancer.* 11 : 280

Hellstrom, K.E. and I. Hellstrom. 1974. Lymphocyte mediated cytotoxicity and blocking serum activity to tumor antigens. *Adv. Immunol.* 18 : 209

Hellstrom, K.E. and I. Hellstrom. 1979. Enhancement of tumor outgrowth by tumor associated blocking factors. *Int. J. Cancer.* 23 : 366

Hellstrom, K.E. and I. Hellstrom. 1991. Principles of tumor immunity to tumor antigens In: Biological therapy of cancer. De Vita V.T., Jr. Hellman, S., Rosenberg, S.A. eds. Lippincott. Philadelphia. pp. 42

Heo, D.S., T.L. Whiteside, J.T. Johnson, K. Chen, E.L. Barnes and R.B. Herbermen. 1987. Lond term interleukin-2 dependent growth and cytotoxic activity of tumor infiltrating lymphocytes from human squamous cell carcinomas of head and neck. *Cancer Res.* 47 : 6353

Herberman, R.B. 1974. Cell mediated immunity to tumor cells. *Adv. Cancer Res.* 19 : 207

Herberman, R.B., M.E. Nunn, H. Lavrin. 1974. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. *Int. J. Cancer.* 15 : 216

Herberman, R.B., M.E. Nunn, H.T. Holden, H. Lavrin. 1975. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. *Int. J. Cancer.* 16 : 230

Herberman, R.B., H.T. Holden, L. Veriso, T. Taniyama, P. Puicetti, H. Kirchner, J. Gerson, S. White, Y. Keisari and J.S. Haskell. 1980. Immunologic reactivity of lymphoid cells in tumors. *Contem. Top. Immunobiol.* 10 : 61

Hewish, D.R. and L.A. Burgoyne. 1973. Chromatin substructure. The digestion of chromatin DNA at regular spaced sites by nuclear deoxyribonuclease. *Biochem. Biophysics. Res. Commu.* 52 : 504

Hibbs, J.B. Jr, L.H. Lambert. Jr. and J.S. Remington. 1972. Control of carcinogenesis : A possible role for the activated macrophage. *Science.* 177 : 998

Hiroshige, N., K. Ishiguro and T. Mori. 1988. Different immune functions of peripheral blood, regional lymphnode and tumor infiltrating lymphocytes in lung cancer patients. *Cancer.* 62 : 2489

Hodes, R.J. and K. S. Hatchock. 1976. *In vitro* generation of suppressor cell activity : Suppression of *in vitro* induction of cell mediated cytotoxicity. *J. Immunol.* 116 : 167

Hollstein, M., D. Sidnansky, B. Vogelstein, C.C. Harris. 1991. p53 mutations in human cancers. *Science.* 253 : 49

Hori, T., N, Kan, K. Ohagaki, N. Nakayama, Y. Nio and T. Inamoto. 1984. Tumor specific cytotoxicity of tumor infiltrating lymphocytes (TIL) induced with TCGF in mammary carcinoma. *J. Japan. Surg. Soc.* 85 : 749

Hori, T., K. Mise, N. Kan, T. Okino, K. satoh, S. Yamasaki, Y. Teramura, T. Harada, K. Ohgaki, H. Kodama and T. Tobi. 1992. Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion. *Biotherapy.* 5 : 21

Horwitz, D.A., N.Kight, A. Temple and A.C. Allison. 1979. Spontaneous and induced cytotoxic properties of human adherent mononuclear cells: Killing of non-sensitized and antibody coated non-erythroid cells. *Immunol.* 36 : 221

Iochim, H.L. 1979. The stroma reaction of tumors: an expression of immune surveillacnce. *J. Nat. Cancer. Inst.* 57 : 465

Itoh, K., A.B. Tilden and C.M. Balch. 1986. Interleukin 2 activations of cytotoxic T lymphocytes infiltrating into human tumors metastatic melanomas. *Cancer Res.* 45 : 3173

Itoh, K., P.D. Chris and C.M. Balch. 1988. Autologus tumor specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: Activation of Interleukin 2 and autologus tumor cells and involvement of the T cell receptor. *J. Exp. Med.* 168: 1419

Jaroslav, B.N. and L. Ortiz-Ortiz. 1971. Hydroxyurea and cell cycle kinetics of cultured antibody forming cells. *Cell. Immunol.* 2 : 164

Jondal, M. and G. Klein. 1975. Classification of lymphocytes in nasopharyngeal carcinoma (NPC). *Biopsies. Biomedicine.* 23 : 163

Jost, L.M., J. Gmuer, O. Eelz, C. Sauter and R.A. Stahel. 1989. Immunotherapy of tumors with interleukin-2 and lymphokine activated killer cells. *Schweiz Med. Wochenschr.* 119 : 137

Judoka, B. E. Spiess, A. Angiolillo, G. Joswig, K. Rothbarth and D. Werner. 1995. High salt and SDS stable DNA

binding protein complexes with ATP-ase and Protein kinase activity retained in chromatin depleted nuclei. *Nucleic Acid Res.* 23 : 1359

Julius, M.H., E. Simpson and A.L. Herzenberg. 1973. A rapid method for isolation of functional thymus derived murine lymphocytes. *Eur. J. Immunol.* **3** : 645

Kastan, M. B, Q. Zhan, W.S. El. Deiry, F.Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett, B. Vogelstein and A.J. Farance. Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 Is defective in Ataxia-Telangiectasia. *Cell.* 71 : 587

Kedar, E. and D.W. Weiss. 1981. The *in vivo* generation of effector lymphocytes and their employment in tumor immunotherapy. Adv. *Cancer Res.* 38 : 171

Keong, A., J. Herman and A.R. Rabson. 1983. Supernatant derived from hepato cellular carcinoma cell line (PLC/PRF/5) depress NK cell activity. *Cancer Immunol Immunother.* 15 : 183

Kiessling. R., E. Klein and H. Wigzell. 1975. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characterization of the killer cell. *Eur. J. Immunol.* 5 : 117

Klein, E., F. Vanky, V. Galili, B.M. Vose and M. Fopp. 1981. Separation and characteristics of tumor infiltrating lymphocytes in man. In : Contemporary topics in immunobiology. M.G. Hanna and I.P. Witz (eds), Plenum, New York. 10 : 79

Klein, G., H.D. Sjorgren, E. Klein and K.E. Hellstrom. 1960. Demonstration of registence against MCA-induced sarcomas in primary autochthonous host. *Cancer Res.* 20 : 1561

Kleinerman, E.S., R. Zicht, P.S. Sarin, R.C. Gallo and I.J. Fidler. 1984. Constitutive production and release of a lymphokine with macrophage-activating factor activity

and distinct from γ-interferon by a human T cell leukemia virus positive cell line. *Cancer Res.* 44 : 4470

Kornberg, R.D. and J.O. Thomas. 1974. Chromatin structure: Oligomers of the histones. *Science* 184 : 865

Kornberg, R.D. 1974. Chromatin structure : A repeating unit of histones and DNA. *Science.* 184 : 868

Kradin, R.L., J.T. Kurnick, D.S. Lazarus, F.I. Freffer, S.M. Dubinett, C.E. Pinto, J. Grifford, E. Davidsom, B.Y. Drove, R. J. Challahan and H. W. Strauss. 1989. Tumor Infiltrating Lymphocytes and Interleukin-2 in treatment of advanced cancer. *Lancet.* 18 : 577

Krahenbuhl, J.L. and J.S. Remington. 1974. The role of activated macrophages in specific and non-specific cytolysis of tumor cells. *J. Immunol.* 113 : 507

Kragel, A.H., W.D. Travis, L. Feinberg, S. Pittaluga, L.M. Striker, W.C. Roberts, M.T. Lotze, J. J. Yang and S.A. Rosenberg. 1990. Pathologic findings associated with interleukine-2 based immunotherapy for cancer : A post mortem study of 19 patients. Hum. Pathol. 21 : 493.

Krishnan, E.C. and W.R. Orwell. 1979. Deficiency of macrophage precurssors in malignancy. Fed. Proc. 38 : 1220

Kuhweide, R., J. V. Damme and J. L. Ceuppens. 1990. Tumor necrosis factor- α and interleukin 6 synergistically induce T cell growth. *Eur. J. Immunol.* 20 : 1019

Kurosawa, S., G. Matsuzaki, H. Mamaru, A. Takashi and N. Kikuo. 1993. Early appearance and activation of NK cells in human tumor-infiltrating lymphoid cells during tumor development. *Eur. J. Immunol.* 23 : 1029

Kurt, R.A., J.A. Park, M.C. Panelli, S.F. Schluter, J.J. Marchalonis, B. Carolus and E.T. Akporiaye. 1995. T lymphocytes infiltrating sites of tumor rejection and progression desplay identical Vβ usage for different cytotoxic activities. *J. Immunol.* 154 : 3969

Lacy, E. and R. Axel. 1975. Analysis of DNA of isolated chromatin subunits. *Proc. Nat. Acad. Sci.* USA. 72 : 3978

Lala, P.K.and L. Kaizer. 1977. Surface markers of small lymphocytes appearing in murine TA. 3(st) solid tumors, host spleen and blood *J. Natl. Cancer. Inst.* 59 : 237

Lala, P.K., V. Santer, H. Libenson and S. Parhar. 1985. Changes in host NK population in mice during tumor development. I. Kinetics and *in vivo* significance. *Cell. Immunol.* 93 : 250

Lamon, E.W., H. Wigzell, E. Klein, B. Anderson and H.M. Skurzak. 1973. The lymphocyte response to primary Moloney Sarcoma virus tumors in Balb/c mice. Defination of the active subpopulations at different times after infection. *J. Exp. Med.* 137 : 1472

Lauder I., and W. Aherne 1972. The significance of lymphocyte infiltrating in neuroblastoma. *Brit. J. Cancer.* 26 : 321

Lee R.E., M.T.Lotze, J.M. Skipper, E. Tucker, R.O. Bonow, F.P. Ognibene, J. A. Carrasquillo, J.H. Srelhamer, J.E. Parrilo and S. A. Rosenberg. 1989. Cardiorespiratory effects of immunotherapy with interleukin-2. *J. Clin. Oncol.* 7: 7

Lefrancois, L., J.R. Klein, V. Paetkau and M. Bevan. 1984. Antigen- Independent activation of memory cytotoxic T cells by interleukin 2. *J. Immunol.* 132 : 1845

LeMay, L.G., J.K. Mitchell, Goedegebuure P.S., W. Harel, and M.S. Mitchell. 1993. Human melanoma-specific $CD4^+$ HLA class I-restricted cytotoxic T-cell clones: Requirements for long term assays and upregulation of antigens with interferon-gamma. *Cancer Immunol Immunother.* 37 : 187

Levy-Wilson, B., and C. Fortier. 1989. The limits of the DNase I sensitive domain of human apoliprotein B gene coincide with the locations of chromosomal anchorage loops and

define the 5' and 3' boundaries of the gene. *J. Biol. Chem.* 264 : 21196

Lewis M.G., J.W. Procatar, D.M.P. Thompson, G. Rowden and T.M. Phillips. 1986. Cellular localization of immunoglobulin with in human malignant melanoma. *Br. J. Cancer.* 63 : 260

Lohr. D. 1975. Yeast Chromatin Subunit structure. *Science* Vol. 188 : 165

Lotz, M.T., E.A. Girmm, A. Mazumder, J.L. Strausser and S.A. Rosenberg. 1981. *In vitro* growth of cytotoxic human lymphocytes. IV. Lysis of fresh and cultured autologus tumor by human lymphocytes cultured in T-cell growth factor (TCGF). *Cancer Res.* 41 : 4420

MacDonald, H.R.. J.C. Cerottini. and K.T. Brunner. 1974. Generation of cytotoxic T lymphocytes *in vitro*. Effect of repeated exposure to alloantigens on the cytotoxic activity of long term mixed leucocyte cultures. *J. Exp. Med.* 140 :718

Maca, R.D., G.D. Bonnard and R.B. Herberman. 1979. The suppression of alloantigen stimulated peripheral blood lymphocytes by cultured human T lymphocytes. *J. Immunol.* 123 : 246

Mace, F.K., J. Ehrke, K. Hori, D.L. Meccublin and E. Mihich. 1988. Role of Tumor necrosis factor in macrophage activation and tumoricidal activity. *Cancer Res.* 48 : 5427

Maeurer, M.J., D.M. Martin, C. Castelli, E. Elder, G. Leder, W.J. Storkus and M.T. Lotze. 1995. Host immune response in renal cell cancer: IL-4 and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. *Cancer Immunol Immunother.* 41 : 111

Maitra, U.K. and A.K. Chakravarty. 1982. Fibrosarcoma - induced angiogenesis and its inhibition in the presence of activated lymphocytes. *Curr.Sci.* 51 : 1012

Maitra, U.K. 1986. Immune response of activated lymphocytes to chemically induced tumor cells. Ph. D. thesis, University of North Bengal. India.

Maitra, U. K. and A. K. Chakravarty. 1990 . Incapaciation of fibrosarcoma cells by polyclonally activated murine T cell. *Indian J. Exp. Biol.* 28 : 308

Mansson, L.A. 1991. Does antibody-dependent epitope masking permit progressive tumor growth in the face of cell mediated cytotoxicity. *Immunol. Today.* 13 : 265

Margolin, K.A., A.A. Rayner, M.J. Hawkins, M.B. Attkins, J. P. Dutcher, R.I. Fisher, G.R. Weiss, J.H. Doroshow, H.S. Jaffe, M.Roper. 1989. Interleukin-2 and lymphokine activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. *J.Clin. Oncol.* 7 : 486

Marincola, F.M., S. Ettinghausen, P.A. Cohen, L.B. Cheshire, N.P. Restifo, J.J. Mule and S.A. Rosenberg. 1994. Treatment of Established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-α. *J. Immunol.* 151 : 3501

Marx, J. 1995. The T cell receptor begins to reveal its many facets. *Science*, 267 : 459

Mastaka, K.T. T.Takashi, T. Takahashi and T. Tokinaga. 1984. A new differentiation antigen (FT1) shared with fetal thymocytes and leukemia cells in mouse. *J. Exp. Med.* 159 : 971

Matsushima, K., K. Onozaki, M. Baczur, and J.J. Oppenheim. 1985. IN: The Physiologic, Metabolic, Immunologic Action of IL-1. Alan R. Liss, New York

McCluskey, R.T. and A.K. Bhar. 1977. Cell mediated reactions *in vivo* . IN: Mechanisms of tumor immunity. Green, I., S. Cohen, R.T. McClusky. eds. John Wiley and Sons Inc. N.Y. pp. 1

McGovern, F.J., H.M. Shaw, C.W. Milton, G. A. Faragp. 1979. Prognastic significance of the histological features of malignant melonoma. *Histopathology*. 3 : 385

McGovern, F.J., H.M. Shaw, C.W. Milton, G. A. Faragp. 1981. Lymphocytic infiltration and survival from malignant melanoma. In: Pathology of malignant melanoma. A. B. Ackerman. (ed). Masson. New York. pp. 341

McKnight, S.L. and O.L. Miller (Jr.) 1976. Ultra sound patterns of RNA synthesis during early embryognesis of Drosophila malanogaster. *Cell*. 8 : 305

Medeiros, L.J., L.J. Picker, A.B. Gelb, J.G. Strickler, S.W. Brain, L.M. Weiss, S. J. Harning and R.A. Warnke. 1989. Number of host "helper" T cells and proliferating cells predict survival in diffuse small-cell lymphomas. *J. Clin. Oncol.* 7 : 1009

Miescher, S. T.L. Whiteside, S. Carrel and V.V. Fliender. 1986. Functional properties of tumor infiltrating and blood lymphocytes in patients with solid tumors: Effect of tumor cell and their supernatant on proliferative response of lymphocytes. *J. Immunol.* 136 : 1899

Mihm MC. and W.H. Clark. 1971. The clinical diagnosis classification and histogenetic concepts of the early stages of cutaneous malignant melanoma. *New Eng. J. Med.* 284 : 1078

Miller, O.L. and B.A. Hamkalo. 1972. In. Molecular Genetics and Developmental Biology. Sussman, M. ed. Prentice-Hall, Englewwd Cliffs, N.J. pp. 183

Miller, R. and R. Phillips. 1969. Separation of cells by velocity sedimentation. *J. Cell. Physiol.* 73 : 191

Moore, M., P.J. Witherow, C.H.G. Price and S.A. Clough. 1973. Detection by immunofluorescence of intracytoplasmic antigens in cell lines derived from human sarcomas. *Int. J. Cancer*. 12: 428

Morgan, D.A., F.W. Ruscetti, and R.C. Gallo. 1976. Selective *in vitro* growth of T lymphocytes from normal human bone marrow. *Science* 193:1007

Morimoto C., N.L. Letvin, J.A. Ditaso, W.R. A.drich and S. F. Schlossman. 1985. The isolation and characterization of the human suppressor inducer T cell subset. *J. Immunol.* 134 : 1508

Mortan, D.L., R.A. Malmgren, E.C. Halmes and A.S. Ketcham. 1988. Demonstration of antibodies against human malignant melanomas by immunofluorescence. *Surgery.* 64: 233

Moy, P.M., and R.L. Coffman. 1989. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. *Ann. Rev. Immunol.* 7 : 145

Mukherjee, B.N., G. Chakraborty and M. Sivanandan. 1990. T-cell clones that reacts against autologus human tumor. **Immunol. Rev.** 116 : 33

Mule, J.J., C.J. Yang, R. Lafrencere, S. Shu and S.A. Rosenberg. 1987. Identification of cellular mechanisms operational *in vivo* during regression of established pulmonary metatases by the systemic administration of high dose recombinant IL-2. *J. Immunol.* 139 : 285.

Mule, J.J., C.J. Yang, S. Shu and S.A. Rosenberg. 1985. The antitumor efficacy of lymphokine activated killer cells and recombinant interleukin-2 *in vivo*. *J. Immunol.* 135 : 646

Mule J.J., J.A. Krosmic and S.A. Rosenberg. 1989. IL-4 regulation of murine lymphokine activated killer activity *in vitro*: Effects on the IL-2 induced expansion cytotoxicity and phenotype of lymphokine activated killer effectors. *J. Immunol.* 142 : 726

Nedrud, J., M. Touton and W. Clark. 1975. Requirment for DNA synthesis and gene expression in the generation of cytotoxicity *in vitro*. *J. Exp. Med.* 142 : 960

Nelson, D.S. 1972. Macrophage are effectors of cell mediated immunity. C.R.C. Cret. Rev. Microbiol 1 : 353

Nethanel, T., R. Kinsky, N. Moav, R. Brown, M. Ran and I.P. With. 1981. Separation of tumor -seeking small lymphocytes and tumor cells using Percoll velocity gradients. *J. Immunol. Methods.* 41 : 43

Nigro, J. M., S.J. Baker, A.C. Preisinger, J.M. Jessup, R. Hostetter, K. Cleary, S.H. Bigner, N. Davidson, S. Baylin, P. Devilee, T. Glover, F. S. Collins, A. Weston, R. Modalii, C.C. Harris and B. Vogelstein. 1989. Mutations in the p53 gene occur in diverse human tumor types. *Nature.* 342 : 705

Noll, M. 1974. Subunit of chromatin. *Nature.* 251 : 249

Nordman, E., I. Lehto and U. Toivanen. 1985. Immune functions and prognosis of patients with solid tumors. *Cancer. Immunol. Immunother.* 20 : 38

North, R.J. and E.S. Dye. 1985. $Lytl^{+}2^{-}$ suppressor T-cells down regulate the generation of $Ly1^{-}2^{+}$ effector T-cells during progressive growth of mastocytoma. *Immunology.* 54 : 47

North, R.J. and I. Bursuker. 1984. The generation and decay of the immune response to a grogressive fibrosarcoma. I. $Lytl^{+}2^{-}$ suppressor T-cell down regulate the generation of $Ly1^{-}2^{+}$ effector cells. *J. Exp. Med.* 159 : 1295

Ognibene, F.P., S.A. Rosenberg, M. Lotze, J. Skibber, M.M. Parker, J.H. Shelhamer, and J.E. Parillo. 1988. Interleukin-2 adminstration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. *Chest.* 94 : 750

Old, L.J. 1985. Tumor Necrosis Factor (TNF). *Science.* 230 : 630

Oliver, J.D., K.W. Kinzer, P. S. Menzer, D. L. George, and B. Vogelstein. 1992. Amplification of gene encoding a p53 associated protein in human sarcomas. *Nature* 358 : 80

Olins, A.L. and D. E. Olins. 1974. Spheroid chromatin units (u bodies). *Science* 183, 330

Oppenheim, J.J., E. J. Kovacs, K. Matshumina and S.K. Durum. 1986. There is more than one interleukin-1. *Immunol. Today.* 7 : 45

Opstelten, D., G.J. Deenen, L. Bos, A. Hermes, L. Murman and P. Nieuwehuis. 1982. Rapid large scale fraction of lymphoid cells by velocity sedimentation at unit gravity, using percoll as separation medium *J. Immunol.* Methods. 48 : 189

Paciucci. P.A., R. Bhardwaj, R. Odehimar, O. Glidewell, and J.F. 1988. Immunotherapy for metastic cancer with recombinant interleukin-2 (rIL-2) by continuous infusion with and without adoptive cell transfer. *Proc. Am. Soc. Clin. Oncol.* 7 : 163

Palladino, M.A., K. Welte, A.M. Carroll and H.F. Oettgen. 1984. Characterization of interleukin 2 (IL-2) dependent cytotoxic T cell clones. V. Transfer of resistance to allografts and tumor grafts requires exogenous IL-2. *Cell Immunol.* 86 : 299

Palmiter R., S. McKnight, E. Mulrihill, and A. Senear. 1977. Cold Spring Harbour *Quant. Biol.* 42 : 639

Pardis, I.L., J.H. Dauber, R.M. Rogers, and B.S. Rabin. 1982. Lymphocyte subset distribution on the margins of lung cancers. *Chest.* 82 : 234

Pardon, J.F., R.I. Cotter, D.H.J. Lilley, D.L. Woster, A.A. Cambell, J.C. Wooley, and B.H. Richards. 1978. IN. *Nucleic acid research.* K. Mizobuchi, I. Watanbe and J.D. Watson (eds). Academic Press Japan Inc. pp. 91

Parkhouse, R.M.E., G. Janossy and M.F. Greaves. 1972. Selective stimulation of IgM synthesis in mouse B lymphocytes by pokweed mitogen. *Nature.* 235 : 21

Pertoft, H, K. Rubin, L. Kjellen, T.C. Laurent and B. Klengeborn. 1977. The viability of cells grown or

centrifuged in a new density gradient medium, Percoll. *Exp. Cell. Res.* 110 : 449

Pierre, F., L.R. Covey, H., Suh, A. Winoto, L. Hood, F.W. Alt. 1989. T cell receptor DJ but not VDJ rearrangement within a recombination substrate introduced into a pre B cell line. *Int. Immunol.* 1 : 66

Pignet, P.E. and P. Vassalli. 1972. Thymus dependent (B) cell proliferation in spleen cell cultures of mouse radiation chimeras stimulated by PHA or allogenic cells. *J. Exp. Med.* 136 : 962

Pilarshim L.M. 1977. A requirement for antigen-specific helper T cells in generation of cytotoxic T cells from thymocyte precursors. *J. Exp. Med.* 145 : 709

Polacow I and R.T. Simpson 1973. Circular dichorism spectra of putative transcribed and repressed chromatin. *Biochem.Biophys. Res. Commu.* 52 : 202

Poppema, S., E.B. Brocker L. de Leu, D. Terbrack, T. Visscher, A.Terhaar, E. Macher, T.H. The, and C. Sorg. 1983 In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. *Clin. Exp. Immunol.* 51 : 77

Prehn, R.J. and J.M. Main. 1957. Immunity to methylcholanthrene induced sarcomas. *J. Natl. Cancer Inst.* 18 : 769

Prehn, R.T. 1960. Tumor specific immunity to transplanted dibez (a,h) authracene-induced sarcomas. *Cancer Res.* 20 : 1614

Pretlow. P.T., E.F. Keith , A.K. Cryar, A.A. Bartolucci, A.M. Pitts, T.G. Pretlow II., P.M. Kimball and E.A. Boohaker. 1982. Eosinophil Infiltration of human colonic carcinoma as a prognostic indicator. *Cancer Res.* 43 : 2997

Pretlow, T.P. and T.G. Pretlow. II 1983, In: *Cell separation : Methods and selected applications.* Vol. 2. eds. T.G. Pretlow II and T.P. Pretlow. Academic Press, Newyork. pp. 63

Rabinowich, H, R. Cohen, I. Bruderman, Z. Steiner, A. Klajman. 1987. Functional analysis of mononuclear cells by infiltrating tumors : Lysis of autologus human tumor cells by culture infiltrating lymphocytes. *Cancer Res.* 47 : 173

Rayner, A.A., R. Lionetto, M.B. Atkins. 1988. Phase II trial of interleukin-2 bolus priming followed by continuous infusion with lymphokine activated killer cells. (IL-2/LAK) in metastatic melanoma. *Proc. Am. Soc. Clin. Oncol.* 7: 246

Ray, P.K. and S. Saha. 1982. Tumor antigen induced generation of humoral and cellular suppressor factors in mice. *Int. J. Cancer.* 12 : 319

Rayser, J.E., J.C. Cerottini and K.T. Brunner. 1978. Generation of cytolytic T lymphocytes *in vitro*. IX. Induction of secondary CTL responses in primary long term MLC by supernatants from secondary MLC. *J. Immunol.* 120 : 370

Reed, J.C., J.D. Alpers, P.C. Nowell and R.G. Hoover. 1986. Sequential expression of protooncogenes during lectin-stimulated mitogens of normal human lymphocytes. *Proc. Natl. Acad. Sci.* (USA). 83 : 3982

Reif, A.E., and J.M.V. Allen. 1964. The AKR thymic antigen and its distribution in leukemias and nervous tissue. *J. Exp. Med.* 120 : 413

Restifo, N.P., F. Esquivel, S. Stotter, R.J. Barth, J.R. Bennink, J.J. Mule, J.W. Yewdell, and S.A. Rosenberg. 1991. Defective presentation of endogeneous antigens by murine sarcoma. Implications for the failure of an anti-tumor immune response. *J. Immunol.* 147 : 1453

Rosenberg, S.A. and W.D. Terry. 1977. Passive immunotherapy of cancer in animals and man. Adv. *Cancer Res.* 25 : 323

Rosenberg, S.A., S. Schwartz and P. J. Spiess. 1978. *In vitro* growth of murine T cells. II. Growth of *in vitro*

sensitized cells cytotoxic for alloantigens. *J. Immunol.* 121 : 1951

Rosenberg, S. A., P. J. Spiess and R. Lafreniere. 1986. A new approach to adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. *Science.* 233 : 1318

Rosenberg S.A, Lotze M.T. Muul L.M,. A.E. Chang, F.P. Avis, S. Leitman, W. M. Lineham, C. N. Robertson, R.E. Lee, J.T. Rubin, C.A. Siepp, C.G. Simpson and D.E. White. 1987. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. *N. Engl. J.Med.* 316 : 889

Rosenberg S.A. Packard B.S., Aebersold, D.S. Suzanne, L.Topalian, S.T. Toy, P. Simon, M.T. Lotze, J.C. Yang. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma : a preliminary report. *N. Engl. J. Med.* 319 : 1676

Rosenberg S.A., M.T.Lotze, J.C. Yang, P.M. Abersold, W.M. Linehan, C.A. Seipp and D.E. White. 1989. Experience with the use of high-dose interleukin-2 in patients. *Annals of Surgery.* 210 : 474

Rosenberg. S.A. P. Aebersold, K. Cornetta, A. Kasid, R. A. Morgan, R. Moem, E. Karson, M.T. Lotze, J.C. Yang. 1990. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. *N. Engl. J. Med.* 323 : 570

Rosenberg S.A. M.T. Lotze, J.C. Yang, L. T. Topalain, A.E. Chang, D.J. Schwartzentruber, P. Abersold, S. Leitman W.M. Linehan, C.A. Seipp, D.E. White, S.M. Steinberg. 1993. Prospective randomized trial of high dose Interleukin-2 alone or in conjunction with lymphokine activated killer cells for the treatment of patients with advance cancer. *J. Natl. Can. Inst.* 85 : 622

Rosenstein, M., T.J. Eberlein and S.A. Rosenberg. 1984. Adoptive immunotherapy of established syngeneic tumors: role of T lymphoid subpopulations. *J. Immunol.* 132 : 2117

Rubbert, A., B. Manger, N. Lang, J.R. Kalden and E. Platzer. 1991. Functional characterization of tumor infiltrating lymphocytes, lymph nodes lymphocytes and peripheral blood lymphocytes from patients with brest cancer. *Int. J. Cancer.* 49 : 25

Ruscetti, F.W., D.A. Morgan and R.C. Gallo. 1977. Functional and norphological characterization of human T cells continuously growing *in vitro*. *J. Immunol.* 119 : 131

Russell, S., G.Y. Gillepespie, C.B. Hansen and C.G. Cochrane. 1976. Inflamatory cells in the solid murine neoplasm. II. Cell types found throughout the course of Moloney sarcoma regression or progression. *Int. J. Cancer.* 18 : 331

Rutter, W.J., R. Picket, and P. Morris. 1973. Towards molecular mechanism of developmental process. Annu. Rev. Biochem. 42 : 601.

Sambrook J., E.F. Fritsch, T. Maniatis 1989. Molecular Cloning. A laboratory manual (2nd. ed.) Cold Spring Harbor Laboratory Press.

Sanders, M.E., M.W. Makgoba, S.O. Sharrow, D. Stephany, T.A. Springer, H.A. Young, S. Shaw. 1988. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CD29, and Pgp-1) and have enhanced IFN-γ production. *J. Immunol.* 140 : 1401

Sanders, M.E., M.W. Makgoba, C.H. June, H.A. Young and S. Shaw. 1989. Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor-mediated activation. *Eur. J. Immunol.* 19 : 803

Schwartzentruber. D., M.T. Lotze and S.A. Rosenberg. 1988. Colonic perforations. An unusual complication of therapy with high dose interleukin-2. *Cancer* (Phila). 62 : 2350

Scheffner, M., B.A. Werness, J.M. Huibregtse, A.J. Levine, P.M. Howley. 1990. The E6 ancoprotein encoded by human papillomavirus Types 16 and 18 promotes the degradation of p53. *Cell.* 63 : 1129

Schichtholz, B., L. Legros, D. Gillet, C. Gaillard, M. Marty, D. Lane, F. Calvo and T. Soussy. 1992. The immune response to p53 in breast cancer patients is directed agaist immunodominant epitopes unrelated to the mutational hotspot. *Cancer Res.* 52 : 6380

Schlunck, T., W. Schraut, G. Riethmuller and H.W. Loms Ziegler- Heitbrock. 1990. Inverse relationship of Ca^{2+} mobilization and cell proliferation in $CD8^{+}$ memory and virgin T cells. *Eur. J. Immunol.* 20 : 1957

Schwartzentruber D., and M.T. Lotze and S.A. Rosenberg. 1988. Colonic perforations. An usual complication of therapy with high dose interleukin-2. *Cancer.* 62 : 2350

Schoof D.D., Y. Terashima, G.E. Peoples, P.S. Goedegebuure, J.V. Raven Andrews, J.P. Richie and T.J. Eberlein. 1993. $CD4^{+}$ T-cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. *Cell Immunol,* 150 : 114

Schwartz, R.H. 1985. T lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. *Annu. Rev. Immunol.* 3 : 237

Seale, L.R. 1978. Chromatin Replication. In: The Cell Nucleus, Part A, Vol. IV. Harris Buch (ed). Academic Press. New York. London. pp. 155

Seung, S. U., and H. Schreiber. 1993. DNA sequence analysis of T-Cell receptor genes reveals an oligoclonal T-cell

response to a tumor with multiple target antigens. *Cancer Res.* 53 : 840

Sevennevig, J.L., C.O. Lunde, J. Holter and D. Bjrgsvik. 1985. Lymphoid infiltration and prognosis in colorectal carcinoma. *Brit. J. Cancer.* 49 : 375

Sevennevig, J.L., O. Closs, M. Harboe and H. Savaar. 1978. Characterization of lymphocytes isolated from non-lymphoid human malignant tumors. *Scand. J. Immunol.* 7 : 487

Shaw, B.R., T.M. Herman, R.T. Kovacic, G.S. Beaudreau and K.E. van Holde. 1976. Analysis of subunit organization in chicken erythrocyte chromatin. *Proc. Natl. Acad. Sci.* 73 : 505

Shu, S., S.A. Rosenberg. 1985. Adoptive immunotherapy of newly induced murine sarcomas. *Cancer Res.* 45 : 1657

Shortman K. W.J. Byrd, J.C. Cerottini and K. T. Brunner. 1973. Characterization and seperation of mouse lymphocyte subpopulation responding to PHA and PWM. *Cell Immunol.* 6 : 251

Simon, R., J. West., A Woods, and K. Bottomly. 1989. Differential activation of cytokine genes in normal CD 4-bearing T cells is stimulant dependent. *Eur. J. Immunol* 19 : 231

Sjogren, H.O., I. Hellstrom, S.C. Bansal and K.E. Hellstrom. 1971. Suggestive evidence that the blocking 'antibodies' of tumor bearing individuals may be antigen-antibody complexes. *Proc. Natl. Acad. Sci.* (USA) 68 : 1372

Slocum, H.K., P.Zlatka, P. Pavelic, M. Youcef, N.Rustum, P.J. Creaven, C. Karakousis, H. Takita and W.R. Greco. 1981. Characterization of cells obtained by mechanical and enzymatic means from human melanoma, sarcoma and lung tumors. *Cancer Res.* 41 : 1428

Smith. H. G., R.P. Harmel, M.G. Hanna, B.S. Zwilling. B. Zbar and H.J. Rapp. 1977. Regression of established interdermal tumors and lymphnode metastases in

guineapigs after systemic transfer of immune lymphoid cells. *J. Natl. Cancer. Inst.* 58 : 1315

Smith, K.A. 1980. T-cell growth factor. *Immunol* 51 : 377

Smith. S.H., M.H. Brown, D. Row, R.E. Callard and P.C.L. Beberley. 1986. Functional subsets of human helper-inducer cells defined by a new monoclonal antibody , UCHL1. *Immunology.* 58 : 63

Sollner-Webb, B. and G. Felsenfeld. 1975. A comparison of the digestion of nuclei and chromatin by staphylococcal nuclease. *Biochemistry* 14 : 2915

Spiess, P.J., J.C. Yang, S.A. Rosenberg. 1987. *In vivo* antitumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2. *J. Natl. Cancer. Inst.* 79 : 1067

Spiess, P.J., J.C. Yang, S.A. Rosenberg. 1988. Tumor infiltrating lymphocytes expanded in recombinant Interleukin-2 mediate potent antitumor activity *in vitro. Cancer Res.* 48: 206

Stahel, R.A., J.P. Sculier, L. Jost. 1988. IL-2 and lymphokine activated killer cells (IL-2/LAK) in solid tumors *Proc. Am. Soc. Clin. Oncol.* 7 : 125

Stahel, R.A., J.P. Sculier, L. Jost, A. Delfarge, D. Bron, J. Gmuver, O. Oelz, C. Saulter, P. Stryckmans and J. Klastersky. 1989. Tolerence and effectiveness of recombinant interleukin-2 (r-met Hu IL-2[ala-125]) and lymphokine activated killer cells in patients with metastatic solid tumors. *Eur. J. Cancer. Clin. Oncol.* 25 : 965

Steven, S., J.L. Urban and H. Schreiber. 1993. DNA sequence analysis of T-Cell receptor genes reveals an oligoclonal T cell response to a tumor with multiple target antigens. *Cancer Res.* 53 : 840

Stobo. J.D. and W.E. Paul. 1973. Functional heterogeneity of murine lymphoid cell. III. Differential responsiveness probe for T cell subsets. *J. Immunol.* 110 : 362

Stovin, S.F., R.D. Lackman, S.Ferrone, P. E. Kiely and M.J. Mastrangelo. 1986. Cellular immune response to human sarcomas: Cytotoxic T cell clones reactive with autologus sarcomas. I. Development, Phenotype and Specificity. *J. Immunol.*137 : 3042

Strausser, J.L. and S.A. Rosenberg. 1978. *In vitro* growth of cytotoxic human lymphocytes. Growth of cells sensitized *in vitro* to alloantigens. *J. Immunol.* 121 : 1491

Stuttman O., E.G. Figarella and R. Wisun. 1980. In "Natural cell mediated immunity against tumors. Herberman R.B. (eds.) Academic press, N.Y. pp. 997

Svedmyr, E. 1975. Long-term maintenance *in vitro* of human T cells by repeated exposure to the same stimulator cells. *Scand. J. Immunol.* 4 : 421

Taglibaue, A., A. Mantovani, M. Kilgllen, R.B. Herberman, and J.L. McCoy. 1979. Natural cytotoxicity of mouse monocytes and macrophages. *J. Immunol.* 122 : 2363

Takahashi, T., M.M. Nau, I. Chiba, J.J. Birrer, R.K. Rosenberg, M. Vinocour, M. Levitt, H. Pass, A.F. Gazdar and J.D. Minna. 1989. p53 a frequent target for genetic abnormalities in lung cancer. *Science* 246 : 491

Takagi, S. K. Chen, R. Schwarz, S. Iwatsuki, R. B. Herberman and T.L. Whiteside. 1989. Functional and phenotypic analysis of tumor infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer 63 : 102

Talmadge, J.E., M. Key and I.J. Filder. 1981. Macrophage content of metastatic and non-metastatic rodent neoplasms. *J. Immunol.* 126 : 2245

Talmadge, J.E., K.M. Meyerst, D.J. Prieur and J.R. Starky. 1980. Role of NK cells in tumor growth and metastasis in beige mice. *Nature*, 284 : 622

Tedder, F.T., M.D. Copper and T. Clement. 1985. Human lymphocyte differentiation antigens HB-10 and HB-11.

II. Differential production of B cell growth and differentiation factors by distinct helper T cell subpopulations. *J. Immunol.* 134 : 2989

Theresa L.W., S. Miescher, H.R. MacDonald and V. Von. Fliender. 1986. Separation of tumor infiltrating lymphocytes from tumor cells in human solid tumors: A comparison between velocity sedimentation and discontinuous density gradients. *J. of Immunol. Methd.* 90 : 221

Thompson D.M.P., S.A. Eccles and P. Alexander. 1973a. Antibodies and soluble tumor specific antigen in blood and lymph of rats with chemically induced sarcoma. *Br. J. Cancer,* 28 : 6

Thompson D.M.P., V. Sellens, S.A. Eccles and P. Alexander. 1973b. Radioimmunoassay of tumor specific transplantation antigen of a chemically induced rat sarcoma. Circulating soluble tumor antigen in tumor bearers. *Br. J. Cancer,* 28 : 377

Tilman, S., W. Schraut, G. Riethmuller and H.W. Loms Ziegler-Heitbrock. 1990. Inverse relationship of Ca^{2+} mobilization and cell proliferation in $CD8^{+}$ memory and virgin T cells. *Eur. J. Immunol.* 20 : 1957

Ting, C.C. 1976. Studies of mechanisms for the induction of *in vivo* tumor immunity. I. Induction of primary and secondary cell mediated cytotoxic response by adoptive transfer of lymphocytes. *Cell. Immunol.* 27 : 71

Topalian S.L., L.M. Muul, D. Solomon and S.A. Rosenberg. 1987. Expansion of human tumro infiltrating lymphocytes for use in immunotherapy trials. *J. Immunol Methods.* 102 : 127

Topalian, S.L. D. Solomon, F.P. Avis, A.E. Chang, D.L. Freerksen, W.M. Linehan, M.T. Lotze, C.N. Robertson, C.A. Seipp, P. Simon, C.G. Simpson, S.A. Rosenberg. 1989. Immunotherapy of patients with advanced cancer using tumor infiltrating

lymphocytes and recombinant interleukin 2: A pilot study. *J. Clin. Oncol.* 6 : 839

Tosi, M.S., and R.S. Weiser. 1968 Mechanism of immunity to sarcoma allograft in the C57BL/KS mouyse. I. Passive transfer studies with immune peritoneal macrophages in X-irradiated host. *J. Nat. Cancer Inst.* 40 : 23

Underwood, J.C.E. 1974. Lymphoreticular infiltration in human tumors: Prognostic and biological implications. A review. *Br. J. Cancer.* 30 : 538

Uotila, M. H.N. rode and J. Gordon. 1978. Blastogenic factor : its role in the mixed leukocyte culture reaction. *Eur. J. Immunol.* 8 : 133

Vink, A., C. Uyttenhove, P. Wauters and J.V. Snick. 1990. Accessory factors involved in murine T cell activation. Distinct roles of interleukin 6, interleukin 1 and tumor necrosis factor. *Eur. J. Immunol.* 20 : 1

van Assendeflt, G.M., O. Hanscomnbe, F. Grosveld and D.R. Greaves. 1989. The β-globin diminant control region activates homologus and heterologus promoters in tissue-specific manner. *Cell.* 56 : 969

Vose, B.M. 1980. Specific T cell mediated killing of autologus lung tumor cell. *Immunol.* 55 : 12

Vose, B.M. 1982a. Separation of tumor and host cell population from human neoplasms. In: Methodologic Surveys. Vol. II. E. Reid (ed). Ellis Hardwood, Chichester. pp 45.

Vose B.M. 1982b. Quantitation of proliferation and cytotoxic precursor cells directed against human tumors : Limiting dilution analysis in peripheral blood and at the tumor site. *Int. J. Cancer*, 30 : 135

Vose, B.M., F. Vanky and E. Klein. 1977. Lymphocyte cytotoxicity against tumor biopsy cells in human. *Int. J. Cancer.* 20 : 512

Vose B.M. and M. Moore. 1985. Human tumor infiltrating lymphocytes : a maker of host response. *Semin Hematol.* 22 : 27

Wagner, H. 1973. Cell mediated immune response *in vitro*: interaction of thymus-derived cells during cytotoxic allograft responses *in vitro*. *Science*. 181 : 1170

Wagner, H. and. M. Rollinghoff. 1976. Secondary cytotoxic allograft responses *in vitro*. *Eur. J. Immunol.* 6 : 15

Wagner, H. and. M. Rollinghoff. 1978. T-T cell interactions inducing *in vitro* cytotoxic allograft response. I. Soluble products from activated $Ly1^{+}T$ cell trigger autonomously antigen primed $Ly23^{+}$ cells to cell proliferation and cytotolytic activity. *J. Exp. Med.* 148 : 1523

Walker, T.M., A.D. Yurochko, C.J. Burger, K.D. Elgert. 1992. Cytokine and suppressor macrophage causes tumor-bearing host $CD8^{+}$ T cells to suppress recognition of allogeneic and syngeneic MHC class II molecules. *J. Leuk Biol.* 52 : 664

Walker, T.M., C.J. Burger, K.D. Elgert. 1993. Tumor growth alters macrophage responsiveness to M-CSF during reactivity against allogeneic and syngeneic MHC class II molecules. *Immunol Invest.* 22 : 463

Wang, P., F. Vanky and E. Klien. 1992. MHC class I restricted autotumor specific $CD4^{+}$, $CD8^{-}$ T cell clones established from autologus mixed lymphocyte tumor culture (MLTC). *Int. J. Cancer*, 51 : 962

Waterfield, J.D., E. M. Waterfield and G. Moller. 1975. Lymphocyte mediated cytotoxicity against tumor cells. I. Con a activated cytotoxic effector cells exhibit immunological specificity. *Cell. Immunol.* 17 : 392

Waterfield, J.D., E. M. Waterfield and G. Moller. 1976. Lymphocyte mediated cytotoxicity against tumor cells. II. Characteristics and tissue distribution of

Concanavalin A activated cytotoxic effector cell. *Eur. J. Immunol.* 6 : 309

Weber, W. T. 1973. Direct evidence for the response of B and T cells to PWM. *Cell Immunol.* 9 : 482

Weinstein, Y. and E. Okan. 1980. *In vivo* T lymphocyte response against sponteneous reticulum cell neoplasm in SJL/S mice. *J. Natl. Cancer. Inst.* 64 : 89

Webb, D.E., A. H. Austin, A. Belldegrun, E. Vaughen, W. M. Linehan and S.A. Rosenberg. 1988. Metabolic and renal effects of interleukin 2 immunotherapy for metastatic cancer. *Clin. Nephrol.* 30 : 141

Weintraub, H. 1973. The assembly of newly replicated DNA into chromatin. Cold Spring Harbour Symp. Quant. Biol 38 : 247

Weintraub, H. and L. Van Frederick. 1974. Disection of Chromosome structure with Trypsin and Nucleases. *Proc. Natl. Acad. Sci.* USA. 71 : 4249

Weintraub, H. 1975. In: Results and problems in cell differentiation. J. Reinert and Holtzer (eds). Springer-Verlag, Berlin. 7 : 27

Weintraub, H and M. Groudine. 1976. Chromosomal subnits in active genes have an altered conformation. *Science.* 193 : 848

Weisbrod, S. 1982. Active Chromatin. *Nature.* 297 : 289

Wells, J.R. 1983. In: Cell separation: Methods and selected applications Vol. 1. eds T.G. Pretlow II and T.P. Pretlow. Academic Press, Newyork. pp. 169

West, W.H., K. W. Tauer, J. R. Yannelli, G.D. Marshall, D.W. Orr, G.B. Thurw and R.K. Oldham. 1987. Constant infusion of recombinant interleukin-2 in adaptive immunotherapy of advance cancer. *N. Eng. J. Med.* 316 : 898

West, W.H., K. W. Tauer, L.S. Schwartzberg, D.G. Marshall, W.D. Orr and R.K. Oldham. 1988. Constant infusion

recombinent interleukin-2 (rIL2) in the treatment of advance renal carcinoma. *Proc. Am. Soc. Clin. Oncol.* 7 : 124

Whiteside, T.L., S. Miescher, J. Hurlimann, L. Moretta and V.von fliender. 1986a. Seperation, phenotyping and limiting dilution analysis of T lymphocytes infiltrating human solid tumors. *Int. J. Cancer.* 37 : 803

Whiteside, T.L., S. Miescher, H.R. MacDonald and V. Von. Fliender. 1986b. Separation of tumor infiltrating lymphocytes from tumor cells in human solid tumors: A comparison between velocity sedimentation and discontinuous density gradients. *J. of Immunol. Methd.* 90: 221

Whiteside.T.L., and R. B. Herberman. 1995. The role of natural killer cells in immune surveillance of cancer. *Curr. Opin. Immunol.* 7 : 704

Whiteside.T.L., L.M. Jost and R. B. Herberman. 1992. Tumor infiltrating lymphocytes: potential and limitations of their use for cancer therapy. *Crit. Rev. Oncol. Hematol.* 12 : 24

Wiebke, Eric. A., S.A. Rosenberg and M.T. Lotze. 1989. Acute immunologic effects of interleukin-2 therapy in cancer patients : Decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. *J. Clin. Oncol.* 6 : 1440

William, E. B., J.C. Palmer, M.A. Alexander, E.P. Cowan and L.A. Manson. 1977. Characterization and specificity of murine anti-tumor cytotoxic effector cells within an ascitic tumor. *J. Immunol.* 118 : 2243

Winter, S.F., J.D. Minna and B.E. Johanson. 1992. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of mutation. *Cancer Res.* 52 : 4168

Wood, G.W., R.A. Morantz, S.A. Tilzer and K.A. Gollahan. 1980a. Immunoglobulin bound *in vivo* to Fc receptor

positive cells in humans central nervous system tumor. *J. Natl. Cancer. Inst.* 64 : 411

Wood, G.W., S.A. Tilzer and K.A. Gollahan, and T. Vats. 1980b. Association between immunoglobulin and IgG Fc receptors in primary methylcholantherene induced sarcomas. Cancer res, 39 : 4588

Wybran, J., I. Hellstrom, K.E. Hellstrom and H.H. Tredenberg. 1974. Cytotoxicity of human rosette forming blood lymphocytes on cultivated human tumor cells. *Int. J. Cancer.* 13: 515

Yang, Y.C., A.B. Ciarletta, P.A. Temble, M.P. Chung, S. Kovacic, J. S. Witek-Giannotti, A.C. Leary, R. Kriz, R.E. Donahue, G.G. Wong and S.C. Clark. 1986. Human 1L-3 (Multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. *Cell.* 47 : 3

Yin. Y., M.A. Taninsky, F.Z. Bischoff, L.C. Strong, G. M. Wahl. 1992. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. *Cell.* 70 : 937

Yokota, T., T. Otsuka, T. Mosann, J. BNanchereau, T. DeFrance, D. Blanchbard, J.E. DeVries, F. Lee and K. I. Arai. 1986 Isolation and characterisation of human interleukin cDNA clone, homologus to mouse B cell stimulatory factor 1, that expresses B cell and T cell stimulating activaties. *Proc. Natl. Acad. Sci.* USA. 83 : 5894

Yoshino, I., T. Yano, M. Murata, T. Ishida, K. Sugimach and G. Kimura. 1992. Tumor reactive T cells accumulate in lung cancer tissue but fail to respond due to tumor derived factors. *Cancer Res.* 52 : 775

Yron, I., T. A. Wood, Jr. P.J. Spiess and S. A. Rosenberg. 1980. *In vitro* growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J. Immuno. 125 : 238

Yurochko, A.D., P.S. Nagarkatti, M. Nagarkatti and K.D. Elgert. 1989. Tumor induced alteration in macrophage accessory cell activity on autoreactive T cells. Cancer Immuno. Immunother. 30 : 170

Zipfel, P.F., S.G. Irving, K.elly and U. Siebenlist. 1989. Complexity of primary genetic response to mitogenic activation of human T cells. *Mol.Cell. Biol.* 9 : 1041

North Bengal University
Library
Raja Rammohanpur